1.Pharmaceutical Care for Tacrolimus-associated Posterior Reversible Encephalopathy Syndrome in A Pediatric Patient with Nephrotic Syndrome
Leli TANG ; Yidie HUANG ; Xunjie ZHANG ; Lin ZHU ; Zhiping LI
Herald of Medicine 2024;43(2):292-298
		                        		
		                        			
		                        			Objective To present a pharmaceutical care case of a pediatric patient with nephrotic syndrome developing tacrolimus-inducedposterior reversible encephalopathy syndrome(PRES)during tacrolimus treatment,and to accumulate experience for the treatment and pharmaceutical services of related diseases.Methods Clinical pharmacists conduct an analysis and evaluation of the correlation of drug-induced PRES caused by tacrolimus in a pediatric patient.Simultaneously,regarding the latest evidence-based information,they propose optimized drug therapy recommendations and provide personalized pharmaceutical services.Results After treatment with antispasmodics,blood pressure control,intracranial pressure reduction,and tapering of tacrolimus,the clinical symptoms of the child improved.Follow-up cranial MRI demonstrated partial absorption of abnormal signals in the brain,and the lesions were significantly smaller than before.Conclusion For tacrolimus-related PRES,clinical pharmacists can enhance the long-term safety and effectiveness of patient medication through aspects such as choosing antihypertensive drugs,adjusting treatment plans based on drug concentration monitoring,and implementing targeted pharmaceutical monitoring and educatio.
		                        		
		                        		
		                        		
		                        	
2.Metagenomic next-generation sequencing for the diagnosis of Pneumocystis jirovecii pneumonia after allogeneic hematopoietic stem cell transplantation
Rong FU ; Ren LIN ; Zhiping FAN ; Fen HUANG ; Na XU ; Li XUAN ; Yifei HUANG ; Hui LIU ; Ke ZHAO ; Zhixiang WANG ; Ling JIANG ; Min DAI ; Jing SUN ; Qifa LIU
Chinese Journal of Hematology 2024;45(1):62-67
		                        		
		                        			
		                        			Objectives:To investigate the value of metagenomic next-generation sequencing (mNGS) in the diagnosis of Pneumocystis jirovecii pneumonia (PJP) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) .Methods:The data of 98 patients with suspected pulmonary infection after allo-HSCT who underwent pathogen detection from bronchoalveolar lavage fluid between June 2016 and August 2023 at Nanfang Hospital were analyzed. The diagnostic performance of mNGS, conventional methods, and real-time quantitative polymerase chain reaction (qPCR) for PJP were compared.Results:A total of 12 patients were diagnosed with PJP, including 11 with a proven diagnosis and 1 with a probable diagnosis. Among the patients with a proven diagnosis, 1 was positive by both conventional methods and qPCR, and 10 were positive by qPCR only. Pneumocystis jirovecii was detected by mNGS in all 12 patients. The diagnostic sensitivity of mNGS for PJP was 100%, which was greater than that of conventional methods (8.3%, P=0.001) and similar to that of qPCR (91.6%, P=1.000) . A total of 75% of the patients developed mixed pulmonary infections, and cytomegalovirus and Epstein-Barr virus were the most common pathogens. Mixed infection was detected in eight patients by mNGS and in five patients by qPCR, but not by conventional methods ( P=0.008) . Conclusions:mNGS had good sensitivity for diagnosing PJP after allo-HSCT and was advantageous for detecting mixed infectious pathogens; therefore, mNGS might be an effective supplement to regular detection methods and qPCR.
		                        		
		                        		
		                        		
		                        	
3.Refractory pneumoparotid in children: a case report and literature review
GE Liangyu ; JI li ; CHEN Lin ; LI Zhiping ; GU Qianping ; MENG Jian ; ZHANG Jing
Journal of Prevention and Treatment for Stomatological Diseases 2023;31(3):192-196
		                        		
		                        			Objective :
		                        			To discuss the treatment of pneumoparotid and to provide a reference for clinical practice. 
		                        		
		                        			Methods:
		                        			 A case of refractory pneumoparotid was reported, and the diagnosis and treatment of parotid emphysema were reviewed and analyzed in combination with the literature.
		                        		
		                        			Results :
		                        			This child had parotid gland enlargement without any obvious cause for more than 1 month. Conservative treatment, such as anti-inflammatory agents, psychological interventions and physical compression were ineffective. The patient had a history of cerebral palsy with epilepsy and involuntary cheek bulging behavior. Therefore, we considered it a refractory case. It was cured after parotid duct ligation and partial parotidectomy of the superficial lobe. A literature review showed that a pneumoparotid is a rare parotid enlargement. Most of the clinical cases were considered to be caused by the return of air into the parotid gland through the parotid duct due to an increase in oral pressure. The diagnosis of pneumoparotid mainly depends on intermittent parotid gland swelling and other clinical manifestations and imaging examination methods, such as ultrasound, CT, MRI and angiography. Its treatment mainly includes conservative anti-inflammatory treatment, physical therapy and psychological intervention. Surgical treatment is indicated for refractory parotid emphysema.
		                        		
		                        			Conclusion
		                        			 Pneumoparotid cases may further develop into parotid inflammation, which is generally treated conservatively. For some severe, recurrent and poor compliance cases, surgical treatment is sometimes needed.
		                        		
		                        		
		                        		
		                        	
4.Parotid duct anastomosis with an epidural catheter as a stent and evaluation of postoperative gland function
GE Liangyu ; JI Li ; CHEN Lin ; LI Zhiping ; GU Qianping ; MENG Jian ; ZHANG Jing
Journal of Prevention and Treatment for Stomatological Diseases 2023;31(4):257-260
		                        		
		                        			Objective :
		                        			To investigate the feasibility of epidural catheters in parotid gland duct anastomosis and the function of the affected side gland after parotid gland duct anastomosis. 
		                        		
		                        			 Methods:
		                        			 Thirteen patients who were treated in the Department of Oral and Maxillofacial Surgery of Xuzhou Central Hospital using an epidural catheter as the scaffold for parotid gland catheter anastomosis were enrolled from Jan. 2019 to June 2021. The swelling, salivary fistula and catheter patency in the parotid gland area were evaluated two weeks after the operation. 99mTcO4- single photon emission computed tomography (SPECT) was used for quantitative detection of salivary gland secretion function
		                        		
		                        			Results:
		                        			 Thirteen patients had no swelling or salivary fistula in the parotid gland area of the affected side two weeks after the operation, and the catheter secretion was unobstructed. There was no significant difference in the uptake rate between the parotid gland on the affected side and the parotid gland on the healthy side (t = -0.859, P = 0.399), and there was no significant difference in the excretion rate between the parotid gland on the affected side and the parotid gland on the healthy side (t = 0.693, P = 0.495). The parotid gland excretion function of the affected side was excellent three months after the operation.
		                        		
		                        			Conclusion 
		                        			Parotid duct anastomosis with an epidural catheter as the stent has good feasibility, and parotid gland secretion function recovers well after the operation, which is worthy of clinical application.
		                        		
		                        		
		                        		
		                        	
5.Short-term effectiveness of orthopedic robot-assisted resection for osteoid osteoma.
Zhuoyu LI ; Weifeng LIU ; Zhiping DENG ; Tao JIN ; Yang SUN ; Yongkun YANG ; Yuan LI ; Fajun YANG ; Feng YU ; Lin HAO ; Qing ZHANG ; Xiaohui NIU
Chinese Journal of Reparative and Reconstructive Surgery 2023;37(11):1319-1325
		                        		
		                        			OBJECTIVE:
		                        			To investigate short-term effectiveness and clinical application advantages of orthopedic robot-assisted resection for osteoid osteoma compared with traditional open surgery.
		                        		
		                        			METHODS:
		                        			A retrospective analysis was conducted on clinical data of 48 osteoid osteoma patients who met the selection criteria between July 2022 and April 2023. Among them, 23 patients underwent orthopedic robot-assisted resection (robot-assisted surgery group), and 25 patients received traditional open surgery (traditional surgery group). There was no significant difference ( P>0.05) in gender, age, disease duration, lesion location and size, and preoperative visual analogue scale (VAS) score, and musculoskeletal tumor society (MSTS) score between the two groups. The surgical time, intraoperative blood loss, intraoperative lesion localization time, initial localization success rate, infection, and recurrence were recorded and compared. VAS scores before surgery and at 24 hours, 1, 3, 6, and 9 months after surgery and MSTS score before surgery and at 3 months after surgery were assessed.
		                        		
		                        			RESULTS:
		                        			All patients completed the surgery successfully, with no significant difference in surgical time between the two groups ( P>0.05). Compared to the traditional surgery group, the robot-assisted surgery group had less intraoperative blood loss, shorter lesion localization time, and shorter hospitalization time, with significant differences ( P<0.05). The initial localization success rate was higher in the robot-assisted surgery group than in the traditional surgery group, but the difference between the two groups was not significant ( P>0.05). All patients in both groups were followed up, with the follow-up time of 3-12 months in the robot-assisted surgery group (median, 6 months) and 3-14 months in the traditional surgery group (median, 6 months). The postoperative MSTS scores of both groups improved significantly when compared to those before surgery ( P<0.05), but there was no significant difference in the changes in MSTS scores between the two groups ( P>0.05). The postoperative VAS scores of both groups showed a gradually decreasing trend over time ( P<0.05), but there was no significant difference between the two groups after surgery ( P>0.05). During follow-up, except for 1 case of postoperative infection in the traditional surgery group, there was no infections or recurrences in other cases. There was no significant difference in the incidence of postoperative infection between the two groups ( P>0.05).
		                        		
		                        			CONCLUSION
		                        			Orthopedic robot-assisted osteoid osteoma resection achieves similar short-term effectiveness when compared to traditional open surgery, with shorter lesion localization time.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Robotics
		                        			;
		                        		
		                        			Blood Loss, Surgical
		                        			;
		                        		
		                        			Osteoma, Osteoid/surgery*
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Postoperative Complications
		                        			;
		                        		
		                        			Bone Neoplasms/surgery*
		                        			
		                        		
		                        	
6.Dynein axonemal heavy chain 10 deficiency causes primary ciliary dyskinesia in humans and mice.
Rongchun WANG ; Danhui YANG ; Chaofeng TU ; Cheng LEI ; Shuizi DING ; Ting GUO ; Lin WANG ; Ying LIU ; Chenyang LU ; Binyi YANG ; Shi OUYANG ; Ke GONG ; Zhiping TAN ; Yun DENG ; Yueqiu TAN ; Jie QING ; Hong LUO
Frontiers of Medicine 2023;17(5):957-971
		                        		
		                        			
		                        			Primary ciliary dyskinesia (PCD) is a congenital, motile ciliopathy with pleiotropic symptoms. Although nearly 50 causative genes have been identified, they only account for approximately 70% of definitive PCD cases. Dynein axonemal heavy chain 10 (DNAH10) encodes a subunit of the inner arm dynein heavy chain in motile cilia and sperm flagella. Based on the common axoneme structure of motile cilia and sperm flagella, DNAH10 variants are likely to cause PCD. Using exome sequencing, we identified a novel DNAH10 homozygous variant (c.589C > T, p.R197W) in a patient with PCD from a consanguineous family. The patient manifested sinusitis, bronchiectasis, situs inversus, and asthenoteratozoospermia. Immunostaining analysis showed the absence of DNAH10 and DNALI1 in the respiratory cilia, and transmission electron microscopy revealed strikingly disordered axoneme 9+2 architecture and inner dynein arm defects in the respiratory cilia and sperm flagella. Subsequently, animal models of Dnah10-knockin mice harboring missense variants and Dnah10-knockout mice recapitulated the phenotypes of PCD, including chronic respiratory infection, male infertility, and hydrocephalus. To the best of our knowledge, this study is the first to report DNAH10 deficiency related to PCD in human and mouse models, which suggests that DNAH10 recessive mutation is causative of PCD.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Semen/metabolism*
		                        			;
		                        		
		                        			Dyneins/metabolism*
		                        			;
		                        		
		                        			Cilia/metabolism*
		                        			;
		                        		
		                        			Mutation
		                        			;
		                        		
		                        			Ciliary Motility Disorders/genetics*
		                        			
		                        		
		                        	
7.Comparison of the efficacy and safety of ShuoTong ureteroscopy and flexible ureteroscopy in the treatment of upper ureteral calculi with CT numberical value greater than 1000 HU
Longhui LAI ; Wenzhao ZHANG ; Dawei LIN ; Peide BAI ; Zhengsheng LIU ; Tao WANG ; Shu CUI ; Zhiping WANG ; Jinchun XING ; Bin CHEN
Chinese Journal of Urology 2023;44(2):115-120
		                        		
		                        			
		                        			Objective:To compare the clinical efficacy and safety of Shuo Tong ureteroscopy(ST-URS) and flexible ureteroscope(FURS)combined with holmium laser lithotripsy in the treatment of upper ureteral calculi with CT numerical value ≥ 1000 HU.Methods:A retrospective analysis of the clinical data of patients of upper ureteral calculi with CT numberical value≥1000 HU in the First Affiliated Hospital of Xiamen University was made from January 2018 to November 2020.There were 61 cases treated with ShuoTong ureteroscopy holmium laser lithotripsy (ST-URS group), including 45 males and 16 females, with 40 on the left and 21 on the right, age of(48.3±12.7) years, body mass index of(24.7±2.7)kg/m 2, the diameter of stone of(1.50±0.45)cm, and the CT numberical value of(1 288.8±179.0)(1 017-1 738)HU. There were 87 cases were treated with flexible ureteroscopy holmium laser lithotripsy (FURS group), including 58 males and 29 females, with 56 on the left and 31 on the right, age of(48.5±13.0) years, body mass index of(24.1±3.8)kg/m 2, the stone diameter of(1.45±0.40)cm, and the CT numberical value of(1 311.3±188.9)(1 009-1 817)HU. There were no significant differences in gender, age, body mass index, the location of stone, the diameter of stone and the CT numberical value of stone( P>0.05)between the two groups. For ST-URS group, a rigid ureteral channel sheath and standard mirror(F7.5/11.5)were placed under direct vision, exiting the standard mirror, leaving the channel sheath, inserting a lithotripsy mirror(F4.5/6.5)and a holmium laser[Power: 8-30 W(0.4-1.0 J/20-30 Hz)], and withdrawing the stone fragments after crushing the stone by "nibbling method" . For FURS group, a hard ureteroscope(F8/9.8)was used to explore the lesion side of the ureter, inserting a guide wire and placing a soft ureteral sheath, then inserting a flexible ureteroscope(F8)for holmium laser lithotripsy, and useing a stone basket to remove larger stone fragments. Ureteral stent was routinely indwelled after the operation. On the day 1 and 1 month after the operation, imaging examinations were performed to evaluate the stone-free rate. No residual stones or the diameter of stone was ≤0.4 cm and no urinary tract infection or any symptoms were defined as stone free. The operation time, blood loss, success rate of stage Ⅰ ureteral access sheath placement, incidence of postoperative complications, stone-free rate(SFR) at 1 day after operation, SFR at 1 month after operation, postoperative hospital stay and hospitalization costs were compared between the two groups. According to the size of calculi, the 2 groups were divided into 2 subgroups(≥1.5 cm and <1.5 cm)in order to make further analysis. The operation time, stone-free rate(SFR) at day 1 after operation and SFR at 1 month after operation were compared between the two groups. Results:The operation time of the ST-URS group was shorter than the FURS group(40.10 min vs. 49.43 min, P=0.020), and the incidence of postoperative complications was lower than the FURS group[3.28%(2/61)vs. 13.79%(12/87), P=0.031]. The SFR at day 1 after operation was significantly higher than the FURS group[60.7%(37/61)vs. 25.3%(22/87), P<0.01], and the hospitalization cost was lower than that of the FURS group(27 686 yuan vs. 32 281 yuan, P<0.010). There were no significant differences in the blood loss[(4.92±9.51)ml vs.(3.95±6.04)ml, P=0.452], success rate of stageⅠureteral access sheath placement[ 96.7%(59/61)vs. 96.6%(84/87), P=1.000], SFR at 1 month after operation[81.97%(50/61) vs. 75.86%(66/87), P=0.375] and postoperative hospital stay[(2.5±1.4)d vs.(2.4±0.8)d, P=0.543] between the two groups. When the size of calculi was ≥1.5cm, the operation time of the ST-URS group was shorter than the FURS group (43.67 min vs 55.00 min), the SFR at 1 day after operation was higher than the FURS group[40.00%(12/30)vs. 9.38%(3/32)], and the above differences are all statistically significant ( P<0.05). Conclusions:Compared with the FURS, for the treatment of upper ureteral calculi with CT numerical value ≥1000 HU, the ST-URS has shorter in operative time, lower in hospitalization cost and incidence of postoperative complications and higher SFR at day 1 after operation. The ST-URS is a safe and effective surgical technique, which is superior in the treatment of larger(≥1.5 cm) stones.
		                        		
		                        		
		                        		
		                        	
8.Expression and prognostic significance of epithelial cell transforming sequence 2 in invasive breast cancer
Zhiping LIN ; Jinfa LIU ; Xiaoyu XIAO ; Jiarong MENG
Chinese Journal of Postgraduates of Medicine 2023;46(9):780-785
		                        		
		                        			
		                        			Objective:To investigate the expression and prognostic significance of epithelial cell transforming sequence 2 (ECT2) in invasive breast cancer.Methods:The clinical data of 165 cases of invasive breast cancer treated in the 909th Hospital of Joint Logistics Support Force from January 2018 to June 2021 were retrospectively analyzed, the tumor tissues and corresponding normal tissues adjacent to the cancer were collected. The tumor tissues of breast cancer and adjacent normal tissues were stained with ECT2 immunohistochemistry. The relationship between the expression of ECT2 protein in different tissues and pathological and clinical data was analyzed. Multivariate Logistic regression was used to analyze the factors affecting the high expression of ECT2 protein. Kaplan-Meier method was used to compare the total survival time of breast cancer patients with high expression of ECT2 and low expression of ECT2 by Kmplot online survival analysis of public databases.Results:The expression of ECT2 in breast cancer tissues was significantly higher than that in adjacent normal tissues: 57.58% (95/165) vs. 12.73% (21/165) ( χ2 = 76.19, P<0.01). The patients with high expression of ECT2 had worse histopathological grade: grade G 1 30.53% (29/95) vs. 57.14% (40/70), grade G 2 40.00% (38/95) vs. 28.57% (20/70), grade G 3 29.47% (28/95) vs. 14.20% (10/40), higher lymph node metastasis: 71.58% (68/95) vs. 7.14% (5/70), worse TNM stage: stage Ⅰ 15.79% (15/95) vs. 34.29% (24/70), stage Ⅱ 27.37% (26/95) vs. 27.14% (19/70), stage Ⅲ 41.05% (39/95) vs. 28.57% (20/70), stage Ⅳ 15.79% (15/95) vs. 10.00% (7/70), higher proportion of menopause: 60.00% (57/95) vs. 44.29% (31/70) and higher Ki-67 proliferation index: 74.74% (71/95) vs. 58.57% (41/70) ( P<0.05). Lymph node metastasis ( OR = 2.764, P = 0.038), histopathological grade G 3( OR = 1.942, P = 0.010), TNM stage Ⅳ ( OR = 2.586, P<0.001), Ki-67 proliferation index greater than 14% ( OR = 1.376, P = 0.006) were the influencing factors of high expression of ECT2 protein in breast cancer patients. The overall survival of ECT2 patients with high expression of breast cancer was even worse ( P<0.05). Conclusions:The expression of ECT2 protein is increased in invasive breast cancer. The prognosis of breast cancer patients with high expression of ECT2 is even worse. ECT2 may be a potential molecular target for breast cancer treatment.
		                        		
		                        		
		                        		
		                        	
9.Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Ph- high-risk B-cell acute lymphoblastic leukemia
Menglin FAN ; Yu WANG ; Ren LIN ; Tong LIN ; Fen HUANG ; Zhiping FAN ; Yajing XU ; Ting YANG ; Na XU ; Pengcheng SHI ; Danian NIE ; Dongjun LIN ; Zujun JIANG ; Shunqing WANG ; Jing SUN ; Xiaojun HUANG ; Qifa LIU ; Li XUAN
Chinese Medical Journal 2022;135(8):930-939
		                        		
		                        			
		                        			Background::Compared with human leukocyte antigen (HLA)-matched sibling donor (MSD) transplantation, it remains unclear whether haploidentical donor (HID) transplantation has a superior graft-versus-leukemia (GVL) effect for Philadelphia-negative (Ph-) high-risk B-cell acute lymphoblastic leukemia (B-ALL). This study aimed to compare the GVL effect between HID and MSD transplantation for Ph- high-risk B-ALL.Methods::This study population came from two prospective multicenter trials (NCT01883180, NCT02673008). Immunosuppressant withdrawal and prophylactic or pre-emptive donor lymphocyte infusion (DLI) were administered in patients without active graft-versus-host disease (GVHD) to prevent relapse. All patients with measurable residual disease (MRD) positivity posttransplantation (post-MRD+) or non-remission (NR) pre-transplantation received prophylactic/pre-emptive interventions. The primary endpoint was the incidence of post-MRD+.Results::A total of 335 patients with Ph- high-risk B-ALL were enrolled, including 145 and 190, respectively, in the HID and MSD groups. The 3-year cumulative incidence of post-MRD+ was 27.2% (95% confidence interval [CI]: 20.2%-34.7%) and 42.6% (35.5%-49.6%) in the HID and MSD groups (P = 0.003), respectively. A total of 156 patients received DLI, including 60 (41.4%) and 96 (50.5%), respectively, in the HID and MSD groups ( P= 0.096). The 3-year cumulative incidence of relapse was 18.6% (95% CI: 12.7%-25.4%) and 25.9% (19.9%-32.3%; P = 0.116) in the two groups, respectively. The 3-year overall survival (OS) was 67.4% (95% CI: 59.1%-74.4%) and 61.6% (54.2%-68.1%; P = 0.382), leukemia-free survival (LFS) was 63.4% (95% CI: 55.0%-70.7%) and 58.2% (50.8%-64.9%; P= 0.429), and GVHD-free/relapse-free survival (GRFS) was 51.7% (95% CI: 43.3%-59.5%) and 37.8% (30.9%-44.6%; P= 0.041), respectively, in the HID and MSD groups. Conclusion::HID transplantation has a lower incidence of post-MRD+ than MSD transplantation, suggesting that HID transplantation might have a superior GVL effect than MSD transplantation for Ph- high-risk B-ALL patients.Trial registration::ClinicalTrials.gov: NCT01883180, NCT02673008.
		                        		
		                        		
		                        		
		                        	
10.Norlichexanthone purified from plant endophyte prevents postmenopausal osteoporosis by targeting ER
Keqi WANG ; Yongyan CHEN ; Shuo GAO ; Maosi WANG ; Mengmeng GE ; Qian YANG ; Mingkai LIAO ; Lin XU ; Junjie CHEN ; Zhiping ZENG ; Haifeng CHEN ; Xiao-Kun ZHANG ; Ting LIN ; Hu ZHOU
Acta Pharmaceutica Sinica B 2021;11(2):442-455
		                        		
		                        			
		                        			Although different types of drugs are available for postmenopausal osteoporosis, the limitations of the current therapies including drug resistances and adverse effects require identification of novel anti-osteoporosis agents. Here, we defined that norlichexanthone (NOR), a natural product, is a ligand of estrogen receptor-alpha (ER
		                        		
		                        		
		                        		
		                        	
            

Result Analysis
Print
Save
E-mail